Reglan Tardive Dyskinesia: What Testing and Evaluation Should You Expect?

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Specific Medication Risks

If you've taken Reglan and notice involuntary movements, you may be concerned about tardive dyskinesia. Decades of medical research have established that certain medications can cause this movement disorder, and understanding the diagnostic process is crucial. This page covers the symptoms, timing, and clinical workup used to evaluate Reglan-related tardive dyskinesia.

Reglan and Tardive Dyskinesia: Medical Evidence and Risk Factors

Reglan (metoclopramide) is a prescription medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults who have not responded to conventional therapy, and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug is not recommended for use in pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms, as well as the risk of methemoglobinemia in neonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is a syndrome of potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The FDA-approved labeling for Reglan includes a boxed warning stating that metoclopramide can cause TD, a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling instructs healthcare providers to use Reglan for the shortest duration of treatment and to periodically reassess the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, the labeling advises avoiding a total duration of treatment with metoclopramide products, including Reglan tablets, for longer than 12 weeks; if longer-term use is unavoidable, the labeling recommends routinely monitoring for signs and symptoms of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Mechanism of Action and Clinical Implications

The mechanistic pathway linking Reglan to TD involves metoclopramide's action as a dopamine receptor antagonist in the central nervous system. Chronic blockade of dopamine D2 receptors in the striatum is believed to lead to upregulation of these receptors and subsequent supersensitivity, which manifests as the involuntary movements characteristic of TD. The labeling notes that metoclopramide may also suppress, or partially suppress, the signs of TD, and may delay the diagnosis of TD because it may mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect can complicate clinical recognition and may allow the condition to progress before it is identified. For patients who develop signs or symptoms of TD, the labeling instructs immediate discontinuation of Reglan (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, the potentially irreversible nature of TD means that even after discontinuation, the movement disorder may persist. The labeling also warns against concomitant use of other drugs known to cause TD, extrapyramidal symptoms, or neuroleptic malignant syndrome, and advises avoiding use in patients with Parkinson's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Legal Considerations and Statute of Limitations in California

From a legal perspective, patients in California who have developed TD after taking Reglan may have claims based on inadequate warnings. The FDA-approved labeling includes a boxed warning about TD risk, but questions may arise about whether prescribers and patients were adequately informed about the specific risks, particularly regarding duration of use and cumulative dosage. The labeling clearly states that Reglan has not been shown to be safe and effective for gastroesophageal reflux for longer than 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite this, some patients may have been prescribed Reglan for extended periods, increasing their risk of TD. The statute of limitations for personal injury claims in California is generally two years from the date of injury or from the date the injury was discovered, or reasonably should have been discovered. For TD, the timeline between exposure and documented harm can be variable. TD may develop after months or years of Reglan use, and symptoms may emerge gradually. The labeling notes that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Patients who took Reglan for longer than the recommended 12-week period may be at higher risk. The date of discovery of TD is critical for statute of limitations purposes. Patients who suspect they have TD should seek medical evaluation promptly to establish a diagnosis and document the timeline of exposure. Attorney considerations for affected patients include gathering medical records that document Reglan prescriptions, duration of use, and any diagnoses of TD. Patients should also obtain records of any warnings provided by prescribers about TD risk. The adequacy of warnings may be evaluated based on whether prescribers followed the labeling instructions regarding duration of use and monitoring. Patients who were not informed about the risk of TD or who were prescribed Reglan for longer than 12 weeks may have stronger claims. In summary, Reglan carries a known risk of causing TD, a potentially irreversible movement disorder. The risk increases with longer treatment duration and higher cumulative doses. Patients in California who developed TD after taking Reglan should be aware of the statute of limitations and seek legal counsel to evaluate their claims. The timeline between exposure and harm is variable, and early diagnosis and documentation are important for both medical management and legal purposes.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan-induced tardive dyskinesia claims in California?

In California, the statute of limitations for personal injury claims is generally two years from the date of injury or from the date the injury was discovered, or reasonably should have been discovered. For tardive dyskinesia caused by Reglan, the timeline can be variable, so it is crucial to seek legal advice promptly to ensure your claim is filed within the applicable deadline.

How does Reglan cause tardive dyskinesia?

Reglan (metoclopramide) is a dopamine receptor antagonist. Chronic blockade of dopamine D2 receptors in the brain can lead to receptor upregulation and supersensitivity, resulting in the involuntary movements characteristic of tardive dyskinesia. The risk increases with longer treatment duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Reglan Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.